| Univariate analysis | Multivariate analysis | ||||
| Variables | No (%) | HR | P value | HR | P value |
| (95% CI) | (95% CI) | ||||
| Age | |||||
| <50 years | 53 (20%) | 1 (Referent) | 1 (Referent) | ||
| >50 years | 211 (80%) | 0.70 | 0.49 | 0.51 | 0.25 |
| (0.25 - 1.92) | (0.17 - 1.59) | ||||
| Nuclear grade | |||||
| 1 - 2 | 179 (68%) | 1 (Referent) | 1 (Referent) | ||
| 3 | 85 (32%) | 2.93 | 0.017 | 3.10 | 0.031 |
| (1.21 - 7.09) | (1.11 - 8.69) | ||||
| Lymphatic invasion | |||||
| Negative | 134 (51%) | 1 (Referent) | 1 (Referent) | ||
| Positive | 130 (49%) | 2.43 | 0.069 | 1.27 | 0.71 |
| (0.93 - 6.34) | (0.36 - 4.56) | ||||
| Venous invasion | |||||
| Negative | 195 (74%) | 1 (Referent) | 1 (Referent) | ||
| Positive | 69 (26%) | 1.39 | 0.47 | 0.55 | 0.31 |
| (0.57 - 3.41) | (0.17 - 1.74) | ||||
| Estrogen receptor | |||||
| Negative | 39 (15%) | 1 (Referent) | 1 (Referent) | ||
| Positive | 225 (85%) | 0.32 | 0.021 | 0.30 | 0.14 |
| (0.12 - 0.84) | (0.06 - 1.50) | ||||
| Progesterone receptor | |||||
| Negative | 69 (26%) | 1 (Referent) | 1 (Referent) | ||
| Positive | 195 (74%) | 0.41 | 0.054 | 0.72 | 0.65 |
| (0.17 - 1.10) | (0.18 - 2.97) | ||||
| HER2 | |||||
| Negative | 218 (83%) | 1 (Referent) | 1 (Referent) | ||
| Positive | 46 (17%) | 1.48 | 0.49 | 0.71 | 0.56 |
| (0.49 - 4.45) | (0.22 - 2.28) | ||||
| Lymph node involvement | |||||
| Negative | 185 (70%) | 1 (Referent) | 1 (Referent) | ||
| Positive | 79 (30%) | 3.32 | 0.0086 | 3.04 | 0.038 |
| (1.36 - 8.13) | (1.07 - 8.67) | ||||
| Tumor size | |||||
| <20mm | 125 (47%) | 1 (Referent) | 1 (Referent) | ||
| >20mm | 139 (53%) | 4.35 | 0.0091 | 3.01 | 0.070 |
| (1.44 - 13.14) | (0.91 - 10.6) | ||||
| PLR | |||||
| <162.3 | 189 (72%) | 1 (Referent) | 1 (Referent) | ||
| >162.3 | 75 (28%) | 2.39 | 0.052 | 3.60 | 0.012 |
| (0.99 - 5.75) | (1.32 - 9.78) | ||||